Agile Therapeutics Inc. buy me8
Start price
27.06.22
/
0%
€79.50
Target price
27.06.23
€100.00
Performance (%)
40.88%
End price
28.06.22
€112.00
Summary
This prediction ended on 28.06.22 with a price of €112.00. With a performance of 40.88% the BUY prediction by me8 was a big success. This prediction was marked as speculative and is excluded from me8's performance statistics.Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Agile Therapeutics Inc. | - | - | - |
| iShares Core DAX® | -0.992% | -3.231% | 11.661% |
| iShares Nasdaq 100 | -0.225% | -3.339% | 36.491% |
| iShares Nikkei 225® | -0.736% | -7.859% | 18.597% |
| iShares S&P 500 | -0.509% | -2.979% | 26.341% |
According to me8 what are the pros and cons of Agile Therapeutics Inc. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Capable Management
Very good company culture
Cons
Little innovation
Comments by me8 for this prediction
In the thread Agile Therapeutics Inc. diskutieren
Buy Agile Therapeutics Inc.
Kursziel gesetzt auf 2,0